C32H47F5O3S
606.8 g/mol
Aktif Farmasötik İngredientTehlike
Fulvestrant
Fulvestrant
CAS129453-61-8EC642-998-6
Kategori
Aktif Farmasötik İngredient
Bileşik Sınıfı
Steroit
Birincil Kullanım
Farmasötik ham madde
Fulvestrant is a steroidal compound derived from 17beta-estradiol, modified with a nonyl group and a pentafluoropentylsulfinyl substituent. It functions as an estrogen receptor antagonist and is used in pharmaceutical manufacturing as an active pharmaceutical ingredient.
Pharmaceutical raw material for hormone-sensitive breast cancer therapiesEstrogen receptor antagonist compound
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 129453-61-8
İlgili Bileşikler
GüçlüBenzer yapıBenzerlik 1.00
(8R,9S,13S,14S,17S)-13-methyl-7-(9-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonylsulfinyl)nonyl)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta(a)phenanthrene-3,17-diol
CAS2482852-42-4
n.a
BenzerBenzer yapıBenzerlik 0.77
(7alpha,17beta)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonyl]estra-1,3,5(10)-triene-3,17-diol
CAS153004-31-0
Fulvestrant intermediate
BenzerBenzer yapıBenzerlik 0.75
Fulvestrant sulfone
CAS98008-06-1
active pharmaceutical ingredient
ReferansAynı kategori
Alclometasone 21-propionate
CAS129459-98-9
corticosteroid active pharmaceutical ingredient
ReferansAynı kategori
Milbemycin oxime
CAS129496-10-2
antiparasitic active pharmaceutical ingredient
ReferansAynı kategori
Glucosamine Sulfate Potassium Chloride
CAS1296149-08-0
active pharmaceutical ingredient
ReferansAynı kategori
Glucosamine sulfate sodium chloride
CAS1296149-13-7
active pharmaceutical ingredient
Referansstereoisomer of
Fulvestrant, 7beta-
CAS407577-53-1
active pharmaceutical ingredient
Güvenlik Referansı
Tehlike
H302Harmful if swallowed
H319Causes serious eye irritation
H360May damage fertility or the unborn child
H362May cause harm to breast-fed children
H373May cause damage to organs through prolonged or repeated exposure
H400Very toxic to aquatic life
H410Very toxic to aquatic life with long lasting effects
H413May cause long lasting harmful effects to aquatic life
Tanımlayıcılar
IUPAC Adı
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
InChIKey
VWUXBMIQPBEWFH-WCCTWKNTSA-N
SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
Eş Anlamlılar (47)
- Fulvestrant (JAN/USP/INN)
- Fulvestrant for system suitability, European Pharmacopoeia (EP)
- Fulvestrant, European Pharmacopoeia (EP)
- Fulvestrant, United States Pharmacopeia (USP)
- FULVESTRANT [MART.]
- Faslodex
- Faslodex (TN)
- Faslodex(ICI 182,780)
- Fluvestrant
- Fulvestrant
- Fulvestrant (Faslodex)
- Fulvestrant (Standard)
- Fulvestrant CRS
- Fulvestrant R enantiomer
- Fulvestrant S enantiomer
- Fulvestrant, >98% (HPLC)
- ICI 182,780
- ICI 182,780 (Fulvestrant)
- fulvestrantum